Artelo biosciences initiates the phase 2a portion of its cares trial evaluatingart27.13 for the treatment of cancer-related anorexia and weight loss

Solana beach, calif., april 25, 2023 (globe newswire) -- artelo biosciences, inc.  (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced it has initiated the phase 2a portion of its cancer appetite recovery study (cares), evaluating art27.13 for the treatment of cancer-related anorexia and weight loss.
ARTL Ratings Summary
ARTL Quant Ranking